December 2016
-
SkyePharma has announced that it has entered into a development, license, and marketing agreement for its Flutiform fluticasone and formoterol combination MDI with Sanofi in Mexico, Central America and South America. Sanofi will submit marketing… Read more . . .
-
According to the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ), the average annual cost of prescription drugs to treat a child with asthma in the US rose from $349… Read more . . .
-
Armstrong Pharmaceuticals is advising customers to stockpile its Primatene Mist epinephrine MDI before the FDA ban on CFC formulations takes effect on December 31, 2011. The company says that it is “actively finalizing its internal… Read more . . .
-
According to Almirall, it has submitted a marketing authorization application to the European Medicines Agency (EMA) for its aclidinium bromide DPI for the treatment of COPD. Aclidinium bromide is a long-acting inhaled muscarinic antagonist; the… Read more . . .
-
Jim Nightingale has been promoted from Senior VP for Business Development and Strategic Alliances to President of drug development company Bend Research. Rod Ray is stepping down as President but will remain as CEO and… Read more . . .
-
A small portion of Gilead’s 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam… Read more . . .
-
Mark Copley of Copley Scientific answers questions about upcoming changes to nebulizer testing requirements. Q: What are the new nebulizer testing requirements, and when do they come into force? A: Both the United States Pharmacopoeia… Read more . . .
-
Abstract submission deadlines for the two largest scientific meetings of OINDP specialists are approaching rapidly. The 22nd Drug Delivery to the Lungs (DDL) meeting will take place December 7-9, 2011 in Edinburgh, UK; Respiratory Drug… Read more . . .
-
Michigan-based biopharmaceutical company NanoBio has announced plans to advance its intranasal influenza vaccine into human trials after publishing results from a successful ferret study of the vaccine. The data gained from the ferret study appears… Read more . . .
-
Acknowledging that in its treatment of asthma and COPD, “we deliver health outcomes that fall some way behind those achieved by the best-performing countries, or the outcomes public health specialists and clinicians tell us are… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland